Preceding and during cancer progression, the immune system is engaged in complex sets of interactions with epithelia that affect tumor incidence and prognosis. Inflammation also has significant effects on gastrointestinal and pancreatic tumors. Moreover, epithelial cell plasticity can significantly alter disease trajectories (for better or worse) via epithelial-to-mesenchymal transition (EMT). Several of the same pathways that regulate EMT are involved in tumor-immune interactions, yet little is known about the mechanisms and consequences of these regulatory processes. Here we introduce a multiscale evolutionary model to describe the interplay between tumor-immune-EMT interactions and their impact on epithelial tissues. Through in silico analysis of large patient cohorts, we found controllable regimes that maximize cancer-free survival. Delaying tumorigenesis depended crucially on properties of the mesenchymal phenotype: its growth rate and its immune-evasiveness. We performed analysis of pancreatic cancer data from The Cancer Genome Atlas to compare clinical measurements with model predictions. We found, in broad agreement with the model, that association with EMT worsened the survival probabilities of inflammation-associated cancer. These results offer novel means to delay disease onset by regulating properties of EMT, and demonstrate the importance of studying cancer-immune interactions in light of EMT.
immune evasion only benefits mutated mesenchymal cells. is simulated in which all the tissue cells experience a random increase in their probability to 133 mutate. From then on, a cell which proliferates also either mutates or increases its probability 134 of mutating later on. Proliferation There are four factors that contribute to the weight of a cell to proliferate. The 144 first is a base proliferation rate that all cells have, p. Second, if the cell has a mutation in the 145 proliferation pathway (δ P = 1), then the weight for proliferation is proportionally increased by 146 ∆ P . Third, if the cell is mesenchymal (ζ = 1), then the weight for proliferation is proportionally 147 decreased by ∆ MGA , which stands for mesenchymal growth arrest. Fourth, there is a negative 148 feedback of the cells on their own proliferation which is quantified by a Hill factor as a function 149 of the tissue cell population, N C , with EC50 term K 0 . In total, the weight for proliferation is 150 given by
Model Simulation
Apoptosis There are two factors that contribute to a cell's weight for undergoing apoptosis.
152
There is a basal apoptosis rate that all cells experience, d C for death. Second, if the cell has 153 a mutation in the apoptosis pathway (δ A = 1), then the weight for undergoing apoptosis is
154
proportionally decreased by ∆ A . In total, the weight for apoptosis is given by 
A similar formula holds for CTLs with only the number of CTLs and their efficacy being different 166 from the above equation.
167
Rest in G 0 The weight associated with quiescence is taken as 1 except in the case of mes-
168
enchymal cells. For mesenchymal cells, the decrease in the probability of proliferation leads to 169 an increase in the probability of quiescence. Hence, the overall weight for quiescence is given
The reason for adding that term is due to the understanding that overall mesenchymal cells 
Completing the Cell Cycle

174
After the cell fates are determined and the results reflected in the system, there are a few 175 things that happen before the system moves on to a new cell cycle. First, the NK and CTL proliferating cells have a cell-specific probability of undergoing a pathway mutation. If they do,
179
one is randomly chosen among the three pathways and the pathway in that cell mutates. If the 180 cell does not undergo a mutation, then its probability of mutation during subsequent cell cycles 181 increases. Finally, the EMT values for each cell is updated. This depends on the cells current
182
EMT score and how much TGF-β is currently in the system. Each cell receives an amount of 183 TGF-β given by
The first term divides up the total TGF-β among all N cells evenly and a Hill function on this quantity is large enough relative to the EMT score of the cell, the cell will undergo EMT. If not,
188
then the cell undergoes the reverse process, MET, and its EMT score will decrease accordingly.
189
Each cell then is relabeled as either epithelial or mesenchymal depending on its new EMT score
190
and whether it is below or above the mesenchymal threshold. Thus, there are two main factors
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that determine if a cell will end a cell cycle as mesenchymal: concentration of TGF-β in the 192 system and the current EMT score of the cell.
193
The amount of TGF-β in the next cell cycle is determined by the number of mutated cells,
194
N MUT , and the number of Tregs, N Treg , each one producing a fixed amount of TGF-β. It is given
Finally, the immune populations are updated. The NKs obey the following differential equation:
which is solved and then discretized over the cell cycle (k) to give
For CTLs and Tregs, they rely on mutant cells being cleared before they can be activated. Let 
Again, solving and discretizing over the cell cycle, we have: 
Mutation and tumorigenesis
205
At the end of each cell cycle, the proportion of tissue cells that are mutated is calculated, and if
206
it is above a certain threshold, a tumorigenic event is recorded and the patient is determined 
Parameter Sensitivity Analysis
211
To study parameter sensitivity, we implemented the Morris method, a one-step-at-a-time global recruitment and death rates [41] . We scaled the model (to reduce the computational burden)
223
to contain on the order of 10 2 tissue cells, whereas a tumor would have on the order of 10 9 224 cells [41] : we thus scaled the relevant parameters for immune populations accordingly. We 225 assigned the priors to be truncated Normal distributions, centered at these estimates. Some of 226 the parameters were also truncated to the right due to physical constraints. The variance for 227 each was set to be twice the mean.
228
The Morris algorithm then computes the average of the absolute change in the output (µ * ),
229
which in the case of this model is the area under the survival curve. 
247
Below we analyze data gathered for pancreatic cancer, denoted by "PAAD" in TCGA. undergoes EMT, the probability that it will proliferate is reduced; if a cell gains a mutation 256 in the apoptosis pathway, the probability that it undergoes apoptosis is greatly reduced. The promotes the recruitment of Tregs, as well as increasing the rate of EMT.
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261
The inflammation cycling scheme for a typical in silico patient consists of alternating high 262 and low regimes (Fig. 1B) ; the inflammation schemes modeled will be discussed in detail in the 
Identifying regulatory parameters via Morris global sensitivity analysis
292
Exploring the parameter spaces of models in systems biology is -in general -a hard problem. 
: Sensitivity analysis of model parameters, determined via the global Morris one-step-at-a-time method. µ * denotes the average absolute change in Time to Cancer when the parameter is varied. RP: relative population; MGA: mesenchymal growth arrest; IHD: inflammation high duration; ILD: inflammation low duration; MIE: mesenchymal immune evasion. Parameters that end "-RU" denote "recruitment up"; parameters that end "-EU" denote "efficacy up".
the model and identify those areas of parameter space that exert the most control, we perform 301 sensitivity analysis.
302
To assess the sensitivity of the model parameters and thus identify those that are most Many parameters in the model change depending on the inflammation state. For the 313 sake of a naming convention, any parameter that includes "low" in the name represents the 314 parameter value when inflammation is low (baseline). When the inflammation is high, these 315 "low" parameters get scaled by the parameters that include "up" in their names. The ILD and 316 IHD parameters determine the duration of low and high inflammation, respectively. A cell with 317 mutated pathways will be affected by the ∆ A , ∆ P , and ∆ IE parameters, depending on whether their secretion of TGF-β is important and we will also study it further. probability that a mutated mesenchymal cell will be subject to immune clearance in a given 333 cycle. The parameter ∆ MGA is the proportional reduction in the probability that a mesenchymal 334 cell will proliferate in a given cell cycle, thus is equivalent (strictly in terms of its impact on 335 the cell cycle) to an increased proportion of time spent resting in the G 0 phase. The cytokine 336 TGF-β is also involved in the EMT process (by increasing the probability of EMT). All three of 337 these parameters were found to have large effects on the model by the Morris OAT analysis 338 presented in Section 3.2.
339
As MIE is increases, the Time to Cancer decreases (Fig. 3A) under all sets of parameters 340 studied: as this subpopulation of cells becomes more resistant to immune clearance, the potential 341 for tumor resilience increases and the tumor can grow faster as a result.
342
As MGA increases, the Time to Cancer increases, i.e. lower proliferation rates for mesenchy-343 mal cells slow cancer growth (Fig 3B) . This is not immediately intuitive, since the decreased 344 proliferation rates affect both mutated and non-mutated tissue cells.
345
TGF-β can be regulated in two ways: its production by mesenchymal cells and its production 346 by Tregs. In Fig 3C, Cancer is monotonic, i.e. increasing either MIE (Fig. 4A-B) or MGA (Fig. 4C-D with respect to MGA (∆ MGA = 0.3). This is seen both for intermittent or low inflammation (Fig.   364   4D ).
365
These striking differences in the mean Time to Cancer -extended by up to one year by predicts that reducing the inflammatory state of the TME in three weeks out of every nine would 368 best prolong cancer-free survival in combination with therapies targeting mesenchymal cells.
369
The control of mesenchymal cell proliferation could become an effective anti-cancer strategy.
370
In contrast, when MIE is varied for different inflammation cycling schemes, regardless of and growth arrest, we study the joint density plot for each of these parameters against the Time
380
to Cancer (Fig. 5) while reducing the ability of a mutated cell to evade the immune system by any amount will 385 improve the probability of cancer-free survival, an optimal value of MGA will prolong survival.
386
To compare these model predictions with experimental studies, we analyzed data from The
387
Cancer Genome Atlas (TCGA) database to study the effects of immune and EMT interactions on 388 prognosis of cancers for which inflammation is known to play an important role, such as colonic 389 or pancreatic cancers [7, 8] . Using gene ontologies as a measure of the effects of inflammatory 390 or EMT processes on cancer-free survival, we investigate pancreatic cancer. We note that the comparison between simulation and data here is indirect since the model studies processes 392 occurring before incidence, while the data address subsequent events, but analogous processes 393 are at play during both the pre-cancerous clonal dynamics addressed by the model, and the 394 progression of disease that follows.
395
For a cohort of pancreatic cancer patients, we cluster the patients via k-means (n = 2) 396 either on gene ontologies relating only to EMT (Fig. 6A) 
